SCHEMBL22017076

SCHEMBL22017076

CCc1ncc2ccccc2c1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
GPR3 P46089 1/20 0.39
PDE10A Q9Y233 2/20 0.37
TLR7 Q9NYK1 1/20 0.36
TRPM8 Q7Z2W7 6/20 0.36
HPGD P15428 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
CCNE2 O96020 1/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
ULK1 O75385 1/20 0.32
POLB P06746 1/20 0.32
RAD52 P43351 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12526215 0.77 GPR3 (0.42) KDM4EGPR3TLR7TRPM8HPGD
SCHEMBL22016467 0.77 POLB (0.37) KDM4ETLR7HPGDCCNE2CDK4
SCHEMBL24390567 0.77 KDM4E (0.39) KDM4EGPR3TLR7TRPM8HPGD
SCHEMBL22035468 0.75 KDM4E (0.44) KDM4EGPR3PDE10ATRPM8POLB
SCHEMBL14533460 0.75 KDM4E (0.44) KDM4EGPR3PDE10AHPGDPOLB
SCHEMBL22037342 0.75 KDM4E (0.40) KDM4EGPR3TLR7TRPM8HPGD
SCHEMBL10272454 0.74 KDM4E (0.42) KDM4EGPR3PDE10APOLBRAD52
SCHEMBL4105404 0.74 KDM4E (0.42) KDM4EGPR3TRPM8HPGDCYP11B1
SCHEMBL21954998 0.74 KDM4E (0.42) KDM4EGPR3TLR7TRPM8HPGD
SCHEMBL30901299 0.74 KDM4E (0.42) KDM4EGPR3TRPM8HPGDCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS GILEAD SCIENCES, INC. 2022-04-21 US disclosed
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin GILEAD SCIENCES, INC. (US) 2022-01-18 US disclosed
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN GILEAD SCIENCES, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155563-A1 COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN ITGB7, ITGB4, ITGA4 KDM4E 1442/4885GPR3 2044/4885PDE10A 994/4885
US-11224600-B2 Compounds for inhibition of alpha 4 beta 7 integrin ITGB7, ITGB4, ITGA4 KDM4E 1442/4885GPR3 2044/4885PDE10A 994/4885
US-20220119383-A1 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS ITGB7, ITGB1, ITGA2B KDM4E 1390/4885GPR3 2006/4885PDE10A 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.